Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Schering AG: PharmaVitae Profile' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Bayer Schering Pharma AG: PharmaVitae Profile |
March 2009 | £3010 | 100 % |
|
Schering-Plough IMS Company Profile |
December 2008 | £510 | 68 % |
|
Schering AG IMS Company Profile |
November 2006 | £249 | 68 % |
|
Bayer Schering Pharma Ag PharmaVitae Profile |
July 2008 | £3010 | 44.5 % |
|
Schering-Plough Corporation - SWOT Analysis |
March 2008 | £66 | 35 % |
|
Schering-Plough Corp: OTC Healthcare |
January 2007 | £195 | 35 % |
|
Schering AG - SWOT Analysis |
October 2008 | £66 | 35 % |
|
Bayer Schering Pharma AG - SWOT Analysis |
March 2008 | £66 | 34.5 % |
|
Schering AG Deals Partneringdesk briefing |
July 2005 | £215 | 28.35 % |
|
Schering-Plough Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 26.25 % |
|
Schering-Plough Corp - OTC Healthcare - World |
December 2008 | £245 | 26 % |
|
ScheringPlough Partnering Guide 2008 |
July 2008 | £195 | 19.25 % |
|
Schering-Plough Corporation PharmaVitae Profile |
July 2008 | £3010 | 19.25 % |
|
Driving Successful Pharma Brands: Case Studies of Real Product Launches |
January 2009 | £4695 | 18 % |
|
Stakeholder Opinion: Erectile Dysfunction Identifying product differentiation and patient segmentation strategies |
December 2006 | £2005 | 16.5 % |
|
Forecast Insight: Multiple Sclerosis Tysabri to prevail despite safety setbacks |
August 2008 | £7600 | 16.5 % |
|
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £1955 | 16.45 % |
|
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape |
August 2008 | £3800 | 16.45 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 16.1 % |
|
Eye Care in United States |
May 2006 | £450 | 14.35 % |
|
Animal Pharm's Top Tier Companies 2007 edition |
January 2007 | £895 | 14 % |
|
NRT Smoking Cessation Aids in United States |
May 2006 | £450 | 14 % |
|
Vitamins And Dietary Supplements in United States |
May 2006 | £450 | 13.65 % |
|
Digestive Remedies in United States |
May 2006 | £450 | 13.65 % |
|
Medicated Skin Care in United States |
May 2006 | £450 | 13.65 % |
|
Tanabe Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 13.5 % |
|
Analytical Tool: Competitive Outlook on HCV |
July 2004 | £1285 | 13.5 % |
|
The Top 50 Pharmaceutical Manufacturing Companies In Ireland |
September 2005 | £285 | 13.5 % |
|
Cough, Cold And Allergy (Hay Fever) Remedies in United States |
May 2006 | £450 | 12.95 % |
|
Rimonabant: The first of the Cannabinoid blockbusters |
June 2007 | £1499 | 11.5 % |
|
Merck & Co. Inc: PharmaVitae Profile |
March 2009 | £3010 | 11.2 % |
|
Hepatitis C - Small-Molecule Antivirals Pave The Way For Triple Therapy Stakeholder Opinions |
December 2007 | £2005 | 10.5 % |
|
Bigpharma Dealmaking Handbook Companies & Contacts |
September 2008 | £1195 | 10.15 % |
|
Bigpharma Dealmaking and Agreements Handbook 2007 Companies, Contacts & Partnering Agreements |
September 2007 | £1195 | 9.1 % |
|
Germany Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 |
March 2009 | £1525 | 8.75 % |
|
The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape |
May 2007 | £1525 | 7.35 % |
|
Pricing and Reimbursement Risk and Opportunity in Pharmaceutical Deal Making |
May 2007 | £1695 | 7 % |
|
U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Products |
March 2006 | £1830 | 6.65 % |
|
Top 7 Cancer Indications Therapeutic & Competitive Insights |
January 2007 | £5960 | 6.65 % |
|
Germany Ophthalmic Devices Investment Opportunities Analysis and Forecasts to 2012 |
July 2008 | £1830 | 6.65 % |
|
The Dermatology Market Outlook to 2013 Competitive Landscape, Pipeline Analysis and Growth Opportunities |
October 2008 | £2025 | 6.65 % |
|
Partnering with Biopharma The definitive guide to bigpharma partnering interests, contacts & agreements |
July 2008 | £1495 | 6.3 % |
|
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends |
November 2007 | £7600 | 6.3 % |
|
Commercial and Pipeline Insight: Hepatitis B |
October 2007 | £7600 | 6.3 % |
|
Fastest Growing Biotechnology Companies, The Growth Strategies, Comparative Analyses and Company Profiles |
March 2008 | £1995 | 5.95 % |
|
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs |
March 2007 | £2005 | 5.95 % |
|
United States Drug Delivery Devices Medical Equipment Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies |
April 2008 | £1830 | 5.6 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £6000 | 5.25 % |
|
United States Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2012 |
September 2008 | £1830 | 5.25 % |
|
Monoclonal Antibodies in Cancer Therapy 2009-2024 |
May 2009 | £1499 | 5.25 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £8000 | 5.25 % |
|
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1830 | 5.25 % |
|
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist |
December 2006 | £2005 | 4.9 % |
|
Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads |
July 2007 | £2005 | 4.9 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1670 | 4.9 % |
|
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1830 | 4.9 % |
|
CNS Drug Discoveries What the Future Holds |
November 2006 | £1995 | 4.55 % |
|
Pipeline/Commercial Insight: Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications |
June 2007 | £7600 | 4.55 % |
|
United States Ophthalmic Devices Medical Equipment Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Cataract Surgery, Refractive Surgery and Vision Care Equipment, Devices and Supplies |
April 2008 | £1830 | 4.55 % |
|
Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success Healthcare |
March 2009 | £2000 | 4.2 % |
|
World Gastrointestinal Disorders Market 2008-2023 |
October 2008 | £1499 | 4.2 % |
|
Stakeholder Insight: Psoriasis Biologics are yet to make topical treatments obsolete |
March 2009 | £8000 | 4.2 % |
|
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market |
April 2008 | £8000 | 3.85 % |
|
Stakeholder Insight: Chronic Leukemias Is there room left for improvement? |
November 2008 | £8000 | 3.85 % |
|
Pipeline Insight: Anxiety Disorders A decade of declining revenues |
March 2006 | £6495 | 3.5 % |
|
Top 10 Biotech Companies Market Outlook, 2008-2023 |
December 2008 | £1499 | 3.5 % |
|
Orphan Drugs to 2008 Understanding regulation & market opportunity in Europe |
January 2005 | £995 | 3.15 % |
|
The Executive Guide to Molecular Imaging |
July 2007 | £595 | 2.8 % |
|
Inflammatory Bowel Diseases World Market Report 2009-2024 |
February 2009 | £1499 | 2.8 % |
|
Therapeutic Monoclonal Antibodies Report 2008-2023 |
July 2008 | £1499 | 2.8 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £2960 | 2.8 % |
|
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012 |
April 2007 | £1499 | 2.45 % |
|
Commercial Insight: Antidyslipidemics Branded statins beware, generics are amongst you |
July 2006 | £8440 | 2.45 % |
|
Sleep Disorders Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking |
March 2009 | £2075 | 2.1 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £260 | 1.4 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009 |
June 2008 | £260 | 1.4 % |
